Advaxis and MedImmune Partner on Immuno-Oncology Combination Clinical Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall St gains as AI earnings lift tech, inflation data supports rate-hold bets
- Oil prices dip as investors weigh lower demand forecasts against US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Aegis Capital Affirms Advaxis (ADXS) at 'Buy'; MedImmune Agreement Could Open Doors to More Licensing
July 22, 2014 11:12 AM EDTAegis Capital affirms Advaxis, Inc. (Nasdaq: ADXS) at Buy with a target price of $15 following news that the company entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (NYSE: AZN).
Analyst Ram Selvaraju said, In our view, the partnership with... More
